ReviewAdvances in virus research2010
Adaptive immunity to the hepatitis C virus.
Review in Advances in virus research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 70 citations in OpenAlex.
- T cell dysfunction and metabolic disruption in chronic hepatitis C virus infection.Frontiers in immunology · 2026Review
- CD96 marks a phenotypically distinct checkpoint-associated HCV-specific CD8+ T-cell subset featuring memory-associated states.Frontiers in immunology · 2026Article
- Design and nonviral delivery of live attenuated vaccine to prevent chronic hepatitis C virus-like infection.Nature communications · 2025Article
- Phenotype and fate of liver-resident CD8 T cells during acute and chronic hepacivirus infection.PLoS pathogens · 2023Article
- Macrophage Depletion Reactivates Fecal Virus Shedding following Resolution of Acute Hepatitis A inJournal of virology · 2022Article
- Adenovirus-vectored T cell vaccine for hepacivirus shows reduced effectiveness against a CD8 T cell escape variant in rats.PLoS pathogens · 2021Article
- Development of a structural epitope mimic: an idiotypic approach to HCV vaccine design.NPJ vaccines · 2021Article
- Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.Journal of virology · 2020Article
- Enhanced T Cell Responses Induced by a Necrotic Dendritic Cell Vaccine, Expressing HCV NS3.Frontiers in microbiology · 2020Article
- Vaccination to prevent T cell subversion can protect against persistent hepacivirus infection.Nature communications · 2019Article
- The relationship between human leukocyte antigen-DP/DQ gene polymorphisms and the outcomes of HCV infection in a Chinese population.Virology journal · 2017Article
- The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C.Immunology · 2017Article
- Regulatory and activated effector T cells in chronic hepatitis C virus: Relation to autoimmunity.World journal of hepatology · 2016Article
- Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.Hepatology (Baltimore, Md.) · 2016Article
- [HCV infection and specific T lymphocyte immunity].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2016Review
- Roles of hepatic stellate cells in liver inflammation: a new perspective.Inflammation and regeneration · 2016Review
- The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.Nature reviews. Microbiology · 2015Review
- Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.PloS one · 2015Article
- T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.Hepatology (Baltimore, Md.) · 2014Article
- Signatures of protective memory immune responses during hepatitis C virus reinfection.Gastroenterology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The hepatitis C virus (HCV) is a global public health problem affecting approximately 2% of the human population. The majority of HCV infections (more than 70%) result in life-long persistence of the virus that substantially increases the risk of serious liver diseases, including cirrhosis and hepatocellular carcinoma. The remainder (less than 30%) resolves spontaneously, often resulting in long-lived protection from persistence upon reexposure to the virus. To persist, the virus must replicate and this requires effective evasion of adaptive immune responses. In this review, the role of humoral and cellular immunity in preventing HCV persistence, and the mechanisms used by the virus to subvert protective host responses, are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.